OCUGEN, INC. Net Income (Loss) Available to Common Stockholders, Diluted
OCUGEN, INC. (OCGN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$24.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$24.88M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$19.18M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$14.74M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$15.35M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$63.08M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$86.80M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$58.37M.
- OCUGEN, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$34.37M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$24.88M 10-Q · filed 2026-08-06 | -$44.05M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$19.18M 10-Q · filed 2026-05-08 | ||||
| 2025-06-30 | -$14.74M 10-Q · filed 2026-08-06 | -$30.09M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$15.35M 10-Q · filed 2026-05-08 | ||||
| 2024-06-30 | -$10.29M 10-Q · filed 2024-08-08 | -$22.22M 10-Q · filed 2024-08-08 | -$31.71M derived: sum of 3 quarters · filed 2024-08-08 | -$45.87M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | -$11.92M 10-Q · filed 2024-05-14 | -$21.42M derived: sum of 2 quarters · filed 2024-05-14 | -$35.58M derived: sum of 3 quarters · filed 2024-05-14 | -$58.64M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-12-31 | -$9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$23.66M derived: sum of 2 quarters · filed 2024-04-16 | -$46.72M derived: sum of 3 quarters · filed 2024-08-08 | -$63.08M 10-K · filed 2024-04-16 | |
| 2023-09-30 | -$14.16M 10-Q · filed 2023-11-09 | -$37.23M derived: sum of 2 quarters · filed 2024-08-08 | -$53.59M 10-Q · filed 2023-11-09 | -$81.94M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-06-30 | -$23.07M 10-Q · filed 2024-08-08 | -$40.39M 10-Q · filed 2024-08-08 | -$67.78M derived: sum of 3 quarters · filed 2024-08-08 | -$89.70M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$17.33M 10-Q · filed 2024-05-14 | -$44.72M derived: sum of 2 quarters · filed 2024-05-14 | -$66.64M derived: sum of 3 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$27.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$49.31M derived: sum of 2 quarters · filed 2024-04-16 | -$86.80M 10-K · filed 2024-04-16 | ||
| 2022-09-30 | -$21.92M 10-Q · filed 2023-11-09 | -$59.41M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | -$14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$25.34M derived: sum of 2 quarters · filed 2022-02-28 | -$51.29M derived: sum of 3 quarters · filed 2022-02-28 | -$58.37M 10-K · filed 2022-02-28 | |
| 2021-09-30 | -$10.76M 10-Q · filed 2021-11-09 | -$36.71M derived: sum of 2 quarters · filed 2021-11-09 | -$43.78M 10-Q · filed 2021-11-09 | -$47.57M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-06-30 | -$25.95M 10-Q · filed 2021-08-06 | -$33.03M 10-Q · filed 2021-08-06 | -$36.82M derived: sum of 3 quarters · filed 2022-02-28 | -$47.29M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-03-31 | -$7.08M derived: 10-K 12 month − 3 quarters · filed 2022-02-28 | -$10.87M derived: sum of 2 quarters · filed 2022-02-28 | -$21.34M derived: sum of 3 quarters · filed 2022-02-28 | -$37.50M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$14.26M derived: sum of 2 quarters · filed 2022-02-28 | -$30.42M derived: sum of 3 quarters · filed 2022-02-28 | -$34.37M 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$10.47M 10-Q · filed 2021-11-09 | -$26.63M derived: sum of 2 quarters · filed 2021-11-09 | -$30.58M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$16.16M 10-Q · filed 2021-08-06 | -$20.10M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | -$20.24M 10-K · filed 2022-02-28 | -$20.24M 10-K · filed 2020-03-27 | |||
| 2018-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$5.16M derived: sum of 2 quarters · filed 2020-03-27 | -$18.22M 10-K · filed 2020-03-27 | -$29.12M 10-K · filed 2019-03-22 | |
| 2018-09-30 | -$7.13M 10-Q · filed 2018-11-08 | -$20.18M 10-Q · filed 2018-11-08 | |||
| 2017-12-31 | -$6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$11.20M derived: sum of 2 quarters · filed 2019-03-22 | -$22.50M 10-K · filed 2019-03-22 | ||
| 2017-09-30 | -$5.08M 10-Q · filed 2018-11-08 | -$16.38M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$31.37M 10-K · filed 2018-03-15 | ||||
| 2015-12-31 | -$32.02M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |